Navigation Links
NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
Date:11/15/2011

SAN FRANCISCO, Nov. 15, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today presented positive preclinical data for NKTR-102, a next-generation topoisomerase I inhibitor, at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer being held in San Francisco, California.  The preclinical data demonstrates that NKTR-102 administered in combination with pegylated liposomal doxorubicin (PLD) in vivo has strong synergistic anti-cancer properties exhibiting a 100% complete response rate with no tumor re-growth in over 90% of animals.  In addition, the study showed that there was no additive toxicity when combining NKTR-102 with PLD in a preclinical model of ovarian cancer.

"Results from these nonclinical studies of NKTR-102 combined with PLD and as a single agent are highly compelling," said Robert Medve, M.D., Chief Medical Officer of Nektar Therapeutics. "In the models of platinum-resistant ovarian cancer, NKTR-102 showed synergistic anti-tumor activity with PLD.  These preclinical data support the future exploration of NKTR-102 in combination with PLD in platinum-resistant ovarian cancer."  

The data presented at the 2011 AACR-NCI-EORTC meeting show that in an in vivo model of platinum-resistant human ovarian cancer, a single-dose of single-agent NKTR-102 resulted in a 100 percent complete response rate and a delay in tumor growth of up to 38 days at the highest dose.  In the same model, multiple doses of single-agent PLD achieved only one partial response and a delay in tumor growth of up to only 24 days at its highest dose.  NKTR-102 administered in combination with PLD showed synergistic anti-tumor activity with a 100 percent complete response rate and no tumor re-growth for 93% of the animals within a 69-day observation period.  

NKTR-102 and PLD Nonclinical DataThese data were pres
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
2. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
3. Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program
4. Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients
5. SomaGenics sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
6. New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
7. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
8. Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment
9. Prototype demonstrates success of advanced new energy technology
10. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
11. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Niceware International , a Milwaukee developer of bar ... seen identification software used to track parts in the ... matter of time before healthcare facilities came calling for ... 2002, has produced NiceLabel software for the automatic identification ...
... since the debut of MedTech Futures and it has been ... share ideas with through this forum. As this column enters ... briefly summarize some of the perspectives over the past year ... - namely personalized medicine. , , Medical technology and pharmaceuticals ...
... the state Division of Enterprise Technology is ... recently released audit of state information technology projects. , ... said he concurs with all the recommendations contained in ... executive-level agencies report by Oct. 1 of this year ...
Cached Biology Technology:Software company enters health space with RFID solutions on hold 2Software company enters health space with RFID solutions on hold 3Personalized medicine and technology convergence 2Personalized medicine and technology convergence 3Personalized medicine and technology convergence 4Personalized medicine and technology convergence 5Personalized medicine and technology convergence 6Personalized medicine and technology convergence 7Personalized medicine and technology convergence 8State technology chief endorses IT audit recommendations 2State technology chief endorses IT audit recommendations 3
(Date:4/23/2014)... 2014) A team of researchers in ... into the brains of nonhuman primates and assessed ... months found that the hNSCs had differentiated into ... tumors. , The study will be published in ... but is currently freely available on-line as an ...
(Date:4/23/2014)... the energy landscape in the U.S., but in ... the energy industry, residents and agricultural interests over ... degraded water quality is a potential risk unless ... in the ACS journal Environmental Science & ... point out that a major criticism of extracting ...
(Date:4/23/2014)... most comprehensive study to date of the family ... more effective vaccine strategies and reveals surprising findings ... results could alter public health strategies to control ... each year. , Genomic analysis of 343 strains ... around the world collected over the last 100 ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2How to avoid water wars between 'fracking' industry and residents 2Impact of whooping cough vaccination revealed 2
... non-human primates, over 100 billion nerve cells build up ... an attempt is made to perform gene therapy for ... specify a responsible neural circuit out of many complicated ... a target gene into this particular circuit selectively. The ...
... has been named founding director of the George Washington ... further strengthen GW,s role as a leader in science ... As director, Dr. Crandall will define the scientific vision ... and implementation of research plans and organizational structures, with ...
... has not changed since the 2010-11 pilot run of the ... University of Arizona-led binational team of researchers. The 15,000-acre ... home to several endangered species and is a major stopover ... It lies within Mexico,s Biosphere Reserve for the Upper Gulf ...
Cached Biology News:Transgenic technique to 'eliminate' a specific neural circuit of the brain in primates 2GW announces creation of Computational Biology Institute to conduct integrated research 2GW announces creation of Computational Biology Institute to conduct integrated research 3GW announces creation of Computational Biology Institute to conduct integrated research 4Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 2Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 3Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 4
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Biology Products: